Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SPN-812 in Preschool-Age Children With ADHD
NCT04781140Phase 4Recruiting
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Mar 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Placebo with SPN-812 (2 arms). Primary endpoint: Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version Total at 6 weeks. Started Mar 2024; status: recruiting.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04781140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781140.